WEBULL
WebtradeDownload

Stoke Therapeutics (STOK) Heads To Guggenheim, Is The 42% Undervaluation Case Convincing?

Simply Wall St · 1d ago

Stoke Therapeutics (STOK) is set to present at the 3rd Annual Guggenheim Healthcare Innovation Conference in Boston on November 10, 2026. The event will give investors fresh commentary from CEO Ian F. Smith and Chief Patient Officer Jason Hoitt.

At a share price of $26.20, Stoke Therapeutics has seen a 16.44% 1 month share price return. However, the 3 month share price return is down 16.21% and the year to date share price return is down 15.21%. The 3 year total shareholder return is more than 6x, pointing to long term investors already experiencing very large gains even as near term momentum has recently cooled.

Spot 20 high quality undiscovered gems that, like Stoke Therapeutics heading into this conference spotlight, are pursuing high-impact therapies while still flying under many investors' radar.

After a sharp 1 month rebound to $26.20 and a wide gap to both analyst targets and intrinsic value estimates, where does fair value for Stoke Therapeutics actually sit as you weigh the next move?

Most Popular Narrative: 41.9% Undervalued

Against the last close of $26.20, the analyst consensus Narrative on Simply Wall St anchors fair value for Stoke Therapeutics at $45.10, which implies a steep discount based on projected revenue growth, margin expansion, and a specific earnings multiple.

In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $177.8 million, earnings will come to $33.6 million, and it would be trading on a PE ratio of 125.9x, assuming you use a discount rate of 7.2%.

Given the current share price of $30.4, the analyst price target of $45.1 is 32.6% higher.

See why 6 investors see Stoke Therapeutics as 42% undervalued.

Result: Fair Value of $45.10 (UNDERVALUED)

Still, that bullish Stoke Therapeutics narrative depends heavily on the Phase 3 Dravet data landing cleanly and on payers accepting rare disease pricing without heavy pushback.

Find out about the key risks to this Stoke Therapeutics narrative.

Next Steps

With sentiment clearly split between long term enthusiasm and near term caution on Stoke Therapeutics, move quickly, review the underlying numbers, and shape your own stance by checking the full balance of 2 key rewards and 1 important warning sign.

Looking for more Stoke Therapeutics style investment ideas?

If Stoke Therapeutics has your attention, do not stop here. Broaden your watchlist with focused stock ideas that match the kind of edge you want.